GVK BIO Enters into Drug Discovery Pact with Wyeth Pharmaceuticals
News May 27, 2008
GVK BIO has announced that it has entered into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth to discover drug candidates focused on pre-defined discovery targets. GVK BIO will utilize in-house capabilities in Discovery Chemistry, Informatics, Biology and ADME to advance this program.
GVK BIO will be responsible for identifying drug candidates, which will be transferred to Wyeth to advance these compounds towards clinical studies. Under the agreement, GVK BIO will receive an initial payment and will be eligible for success-based milestone payments.
Mr. G V Sanjay Reddy, Managing Director, GVK Biosciences said “It is a momentous occasion for us. GVK BIO has had a successful partnership with Wyeth on various chemistry research activities dating to 2006. This research agreement expands our work together and builds on GVK BIO’s core strengths. This agreement further validates India’s capability to do innovative research along with leading pharmaceutical and biotech companies”.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE